

November 26, 2019

Recent Drug Formulary Updates: November 2019

- Generic *Ezetimibe* and *Rosuvastatin* are now on formulary!
- A one-month supply of Truvada® and Isentress® or Tivicay® have been added to the Advanced Health formulary to expediate access to post exposure HIV prophylaxis (PEP). A contracted retail pharmacy may dispense the 30-day supply. Use greater than 30 days requires a prior authorization and dispensing from our contracted specialty pharmacy.
- AirDuo® (*fluticasone/salmeterol*) and Wixela® (*fluticasone/salmeterol*) inhalers are available on formulary with a prior authorization.

Effective January 1, 2020

- *Buprenorphine* and *buprenorphine/naloxone* products for opioid use disorder will be available without a prior authorization for dosing up to 24mg/day.
- *Injectable naltrexone* will be available on formulary without a prior authorization.
- *Cefdinir* tablets were added to formulary.
- Zepatier® will be removed from the Advanced Health formulary consistent with the Oregon Health Authority Preferred Drug List and Hepatitis C Direct Acting Antivirals Drug Use Criteria. Please reference Oregon Medicaid Fee-For-Service drug use criteria for guidance on coverage and treatment selection at: https://www.orpdl.org/durm/PA_Docs/HepatitisC_DAAs.pdf
- A prior authorization will be required for Novolog® and Humalog®. The preferred rapid acting insulin will be Admelog®. Please transition your patients to Admelog® as soon as possible to prevent delays. If your patient requires continued therapy with Humalog® or Novolog®, please submit prior authorization for review.
- *Alogliptin* will be added to formulary with a step therapy edit requiring a trial of metformin and sulfonylurea. If a trial of metformin and sulfonylurea is not medically appropriate for your patient, a prior authorization may be submitted with documentation outlining the clinical rationale for exception.